Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIBF1120 in Recurrent and Platinum-Sensitive SCLC
NCT02152059Phase 2Withdrawn
- Sponsor
- American Health Staffing Group
- Start
- Jul 2014
- Primary completion
- Jul 2016
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of nintedanib in small cell lung cancer (SCLC), sponsored by American Health Staffing Group. Planned start Jul 2014; status: withdrawn.
02
Drugs
nintedanib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02152059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02152059.